Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.9 Billion CNY | -21.06% |
| 2022 | 2.4 Billion CNY | 2.26% |
| 2021 | 2.35 Billion CNY | -24.96% |
| 2020 | 3.13 Billion CNY | 33.25% |
| 2019 | 2.35 Billion CNY | -3.87% |
| 2018 | 2.44 Billion CNY | 34.63% |
| 2017 | 1.81 Billion CNY | -13.17% |
| 2016 | 2.09 Billion CNY | 17.35% |
| 2015 | 1.78 Billion CNY | 77.65% |
| 2014 | 1 Billion CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | -100.0% |
| 2009 | 64 Million CNY | -15.79% |
| 2008 | 76 Million CNY | -5.0% |
| 2007 | 80 Million CNY | -32.2% |
| 2006 | 118 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.57 Billion CNY | -12.58% |
| 2024 Q1 | 1.8 Billion CNY | -9.92% |
| 2023 Q4 | 1.9 Billion CNY | -13.99% |
| 2023 FY | 1.9 Billion CNY | -21.06% |
| 2023 Q1 | 2.6 Billion CNY | 8.22% |
| 2023 Q2 | 2.36 Billion CNY | -9.2% |
| 2023 Q3 | 2.2 Billion CNY | -6.6% |
| 2022 Q3 | 2.27 Billion CNY | 34.1% |
| 2022 FY | 2.4 Billion CNY | 2.26% |
| 2022 Q1 | 2.2 Billion CNY | -6.38% |
| 2022 Q4 | 2.4 Billion CNY | 5.92% |
| 2022 Q2 | 1.69 Billion CNY | -23.1% |
| 2021 Q3 | 3.06 Billion CNY | -2.7% |
| 2021 Q1 | 3.25 Billion CNY | 3.72% |
| 2021 Q2 | 3.14 Billion CNY | -3.3% |
| 2021 FY | 2.35 Billion CNY | -24.96% |
| 2021 Q4 | 2.35 Billion CNY | -23.11% |
| 2020 FY | 3.13 Billion CNY | 33.25% |
| 2020 Q3 | 2.94 Billion CNY | -16.29% |
| 2020 Q4 | 3.13 Billion CNY | 6.5% |
| 2020 Q2 | 3.51 Billion CNY | 19.57% |
| 2020 Q1 | 2.94 Billion CNY | 25.01% |
| 2019 Q3 | 1.76 Billion CNY | -8.86% |
| 2019 Q4 | 2.35 Billion CNY | 33.77% |
| 2019 Q1 | 2.32 Billion CNY | -5.0% |
| 2019 Q2 | 1.93 Billion CNY | -17.0% |
| 2019 FY | 2.35 Billion CNY | -3.87% |
| 2018 Q4 | 2.44 Billion CNY | -0.7% |
| 2018 FY | 2.44 Billion CNY | 34.63% |
| 2018 Q3 | 2.46 Billion CNY | 27.04% |
| 2018 Q2 | 1.94 Billion CNY | -6.9% |
| 2018 Q1 | 2.08 Billion CNY | 14.64% |
| 2017 Q4 | 1.81 Billion CNY | -22.71% |
| 2017 FY | 1.81 Billion CNY | -13.17% |
| 2017 Q3 | 2.35 Billion CNY | 7.06% |
| 2017 Q2 | 2.19 Billion CNY | 0.31% |
| 2017 Q1 | 2.19 Billion CNY | 4.62% |
| 2016 Q1 | 1.72 Billion CNY | -3.18% |
| 2016 FY | 2.09 Billion CNY | 17.35% |
| 2016 Q3 | 1.04 Billion CNY | -13.54% |
| 2016 Q4 | 2.09 Billion CNY | 99.7% |
| 2016 Q2 | 1.21 Billion CNY | -29.8% |
| 2015 Q2 | 1.12 Billion CNY | -1.47% |
| 2015 Q1 | 1.14 Billion CNY | 13.75% |
| 2015 Q3 | 2.53 Billion CNY | 125.22% |
| 2015 FY | 1.78 Billion CNY | 77.65% |
| 2015 Q4 | 1.78 Billion CNY | -29.62% |
| 2014 Q3 | 538.95 Million CNY | -0.0% |
| 2014 Q2 | 538.98 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 1 Billion CNY | 86.48% |
| 2014 FY | 1 Billion CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2010 Q1 | 64 Million CNY | 0.0% |
| 2010 FY | - CNY | -100.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 Q3 | - CNY | -100.0% |
| 2010 Q2 | 52 Million CNY | -18.75% |
| 2009 FY | 64 Million CNY | -15.79% |
| 2009 Q2 | 70 Million CNY | 0.0% |
| 2009 Q4 | 64 Million CNY | 0.0% |
| 2008 FY | 76 Million CNY | -5.0% |
| 2007 FY | 80 Million CNY | -32.2% |
| 2006 FY | 118 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -91575.788% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | -91.958% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | -1522.586% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | -588.066% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -2590.467% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -5170.689% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -14746.013% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -2243.529% |
| SSY Group Limited | 1.94 Billion HKD | 2.42% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -4238.9% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | -220.912% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 88.563% |